# MRAS Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The MRAS gene encodes a unique RAS GTPase with low intrinsic GTPase activity, functioning as a critical molecular switch in signal transduction pathways regulating cell proliferation, differentiation, and survival. Its distinct effector preference, particularly for PI3K and RalGDS, differentiates it from other canonical RAS proteins.
- Germline activating mutations in MRAS, such as p.G23V, cause a severe form of Noonan syndrome characterized by a high incidence of early-onset hypertrophic cardiomyopathy, distinctive facial features, and neurodevelopmental delay. Genetic testing is recommended for patients with Noonan syndrome and severe cardiac anomalies.
- Common single-nucleotide polymorphisms (SNPs) at the MRAS locus (3q22.3), notably rs9818870, are repeatedly associated with increased risk for coronary artery disease and ischemic stroke across diverse ethnic populations, suggesting a role in atherosclerotic pathogenesis.
- Somatic MRAS alterations, including the recurrent p.Q71R mutation, are implicated in various malignancies such as gastric cancer and contribute to acquired resistance to targeted therapies like osimertinib in lung adenocarcinoma by reactivating MAPK and PI3K/AKT pathways.
- The SHOC2–MRAS–PP1 holophosphatase complex is a key regulatory hub where MRAS-GTP recruits SHOC2 and PP1 to dephosphorylate and activate RAF kinases, a mechanism central to both Noonan syndrome pathogenesis and oncogenic signaling.
- Therapeutic strategies for MRAS-driven pathologies include direct targeting of the MRAS-SHOC2 interaction and indirect inhibition of downstream effectors via MEK, PI3K, or AKT inhibitors, with pharmacogenomic studies exploring MRAS variants' influence on drug response, such as clopidogrel resistance.

---

## Executive Summary & Key Metadata

The **MRAS** gene (Muscle RAS Oncogene Homolog) encodes a member of the RAS superfamily of small GTPases, functioning as a critical molecular switch in signal transduction cascades that regulate cellular proliferation, differentiation, survival, and migration. Unlike the prototypical HRAS, KRAS, and NRAS isoforms, MRAS (also known as M-Ras or R-Ras3) exhibits unique biochemical properties, including a markedly reduced intrinsic GTPase activity and a distinct preference for effector engagement, positioning it as a "broken switch" within the GTPase family [1]. This functional divergence underlies its specialized roles in development, particularly in cardiomyocyte growth, neural function, and embryonic stem cell pluripotency [2, 3, 4].

Clinically, MRAS has emerged as a gene of significant translational importance. Germline activating mutations in MRAS cause a severe form of **Noonan syndrome** (NS), a RASopathy characterized by distinctive facial features, short stature, cardiac defects—most notably hypertrophic cardiomyopathy (HCM)—and variable neurodevelopmental delay [1, 5, 6, 7]. Concurrently, common single-nucleotide polymorphisms (SNPs) at the 3q22.3 locus have been repeatedly associated with increased risk for **coronary artery disease (CAD)**, ischemic stroke, and other atherosclerotic phenotypes in multiple ethnic populations [2, 3, 4, 5, 6, 7]. Somatic alterations and aberrant expression of MRAS have also been documented in various malignancies, including gastric cancer, lung adenocarcinoma (particularly in the context of osimertinib resistance), and breast cancer [1, 2, 3]. The recent elucidation of the SHOC2–MRAS–PP1 holophosphatase complex has provided a structural and mechanistic framework for understanding how MRAS mutations drive pathology and has opened new avenues for targeted therapeutic intervention [4, 5].

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | MRAS |
| **UniProt Accession** | O14807 |
| **Representative PDB ID** | True (e.g., 3K5Y, 4GBN; see Section 2) |
| **Chromosomal Locus** | 3q22.3 |
| **Primary Molecular Function** | Small GTPase; signal transduction; molecular switch in RAS/MAPK and PI3K/AKT pathways |
| **Disease & Pathology Associations** | Noonan syndrome (with hypertrophic cardiomyopathy), coronary artery disease, ischemic stroke, gastric cancer, lung cancer (therapy resistance), breast cancer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The human *MRAS* gene is located on the **long arm of chromosome 3 at band q22.3** (genomic coordinates: chr3:138,347,648-138,405,613 on GRCh38/hg38). This locus is situated within a gene-dense region that has been repeatedly implicated in cardiovascular disease susceptibility through genome-wide association studies (GWAS) [4, 6, 7]. The region contains a cluster of genes, including *MRAS*, *HEG1*, and others, making the assignment of causal variants to a specific gene challenging; however, functional studies have increasingly pointed to MRAS as a primary effector [1, 4].

The gene spans approximately **58 kilobases** of genomic DNA and is transcribed from the minus strand. The canonical transcript (NM_012219.4) comprises **6 exons** and **5 introns**, with the translation initiation codon located in exon 1 and the stop codon in exon 6. The coding sequence is 624 nucleotides in length, encoding a protein of **208 amino acids** with a predicted molecular mass of approximately 23.5 kDa.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' flanking region of *MRAS* lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and developmentally regulated genes. Multiple **CpG islands** are present in the proximal promoter, and their methylation status has been shown to modulate MRAS expression in a cell-type-specific manner. In silico promoter analysis predicts binding sites for several transcription factors, including **SP1**, **AP-1 (JUN/FOS)**, **ETS family members**, and **STAT3**. The potential for STAT3 binding is particularly intriguing given the established role of unphosphorylated STAT3 (U-STAT3) in transcriptional regulation and oncogenesis [1, 7]; however, direct regulation of MRAS by U-STAT3 remains to be experimentally validated.

**Enhancer elements** within the 3q22.3 locus have been identified through chromatin state annotations (H3K27ac and H3K4me1 marks) in human coronary artery smooth muscle cells (CASMCs) and endothelial cells. These enhancers physically interact with the MRAS promoter via chromatin looping, as demonstrated by Hi-C data, and are hypothesized to mediate the effects of non-coding risk variants at this locus [4]. The risk allele at the sentinel SNP **rs9818870**, located in intron 1 of MRAS, falls within a region of open chromatin and may disrupt transcription factor binding, leading to altered MRAS expression levels [2, 3, 4].

### 1.3 Alternative Splicing and Isoforms

While the full-length 208-amino-acid protein is the predominant isoform, transcriptomic analyses have identified several minor splice variants:

- **Isoform 2 (ΔExon 3)**: An in-frame deletion of exon 3 results in a protein lacking residues 89-123, which encompasses part of the switch II region and the interswitch domain. This isoform is predicted to have altered nucleotide exchange properties and is expressed at low levels in the brain and heart.
- **Isoform 3 (3' UTR extended)**: A variant utilizing an alternative polyadenylation signal in exon 6, producing a longer 3' untranslated region (UTR). This extended UTR contains additional binding sites for microRNAs (miRNAs), including miR-143 and miR-145, which are known regulators of smooth muscle cell phenotype [4]. Disease-associated SNPs within this region could alter miRNA-mediated regulation by disrupting RNA secondary structure [4].

The functional significance of these isoforms remains an active area of investigation, but their existence underscores the complex post-transcriptional regulation of MRAS.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The MRAS protein is a member of the RAS subfamily of small GTPases, sharing approximately 50% sequence identity with HRAS, KRAS, and NRAS. The highest sequence conservation is observed in the G-box motifs (G1-G5) responsible for nucleotide binding and hydrolysis. The domain architecture is as follows:

| **Domain/Region** | **Residues** | **Function** |
| :--- | :--- | :--- |
| **N-terminal Hypervariable Region (HVR)** | 1-15 | Membrane targeting; contains a polybasic region and a palmitoylation site (Cys11) |
| **G1 (P-loop)** | 16-23 | Binds the β-phosphate of GDP/GTP; consensus sequence GXXXXGKS/T |
| **Switch I** | 32-40 | Conformational change upon GTP binding; interacts with effectors and GAPs |
| **G2 (Switch I)** | 32-40 | Threonine 35 coordinates Mg²⁺ ion |
| **Switch II** | 59-72 | Conformational change; contains catalytic glutamine (Gln71) |
| **G3 (DXXG)** | 57-60 | Binds Mg²⁺ and γ-phosphate |
| **G4 (NKXD)** | 116-119 | Binds guanine ring; determines nucleotide specificity |
| **G5 (SAK)** | 145-147 | Stabilizes the guanine nucleotide-binding pocket |
| **C-terminal Hypervariable Region (HVR)** | 181-208 | Membrane localization; contains CAAX box (Cys-Leu-Ser-Ser) for farnesylation |

### 2.2 Tertiary and Quaternary Structure

The three-dimensional structure of MRAS, solved by X-ray crystallography (e.g., PDB entries 3K5Y for the GppNHp-bound form and 4GBN for the GDP-bound form), reveals the canonical RAS fold: a six-stranded β-sheet (β1-β6) flanked by five α-helices (α1-α5). The nucleotide-binding pocket is formed by the P-loop (residues 16-23) and the G4/G5 motifs, with the guanine base sandwiched between the β2 strand and the α2 helix.

**Critical Structural Features:**

1. **Switch Regions**: The Switch I (residues 32-40) and Switch II (residues 59-72) regions undergo significant conformational rearrangements upon GTP hydrolysis. In the GTP-bound state, these regions adopt a "closed" conformation that creates a high-affinity binding surface for downstream effectors. In the GDP-bound state, they are more flexible and solvent-exposed.

2. **The "Broken Switch" Phenomenon**: A defining structural feature of MRAS is its **intrinsically low GTPase activity**. The catalytic glutamine (Gln71, analogous to Gln61 in HRAS) is present, but the positioning of the catalytic machinery is suboptimal. Structural studies have shown that the Switch II region in MRAS adopts a conformation that does not properly align Gln71 with the attacking water molecule, resulting in a ~100-fold reduction in intrinsic GTP hydrolysis compared to HRAS [1]. This has led to the designation of MRAS as a "broken switch," as it relies heavily on GTPase-activating proteins (GAPs) to cycle back to the inactive state.

3. **Unique Insert Region**: MRAS contains a unique insertion of three residues (Gly-Glu-Pro) between the Switch II region and the α2 helix (residues 73-75). This insertion alters the conformation of the α2 helix and contributes to the distinct effector specificity of MRAS. Specifically, it enhances binding to the RBD (Ras-binding domain) of certain effectors, such as **RalGDS** and **PI3K**, while reducing affinity for the classical RAF kinases compared to HRAS.

4. **C-terminal Membrane Anchor**: The C-terminal HVR (residues 181-208) contains a CAAX box (Cys-Leu-Ser-Ser) that undergoes post-translational farnesylation at Cys205, followed by proteolytic cleavage of the AAX residues and carboxymethylation. Additionally, a palmitoylation site at Cys181 facilitates stable membrane association. These lipid modifications are essential for proper subcellular localization and signaling function.

### 2.3 Interactive 3D Visualization

For a comprehensive structural exploration, including the spatial arrangement of the switch regions, the nucleotide-binding pocket, and the unique insert domain, please utilize the interactive visualizer:

[Interactive 3D Protein Visualizer: Load MRAS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14807)

This tool allows for the manipulation of the protein structure, highlighting of specific residues, and visualization of the GDP/GTP-bound conformations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The RAS/MAPK Signaling Cascade

MRAS functions as a molecular switch in the RAS/MAPK (Mitogen-Activated Protein Kinase) pathway, a signaling cascade that transduces extracellular growth factor signals to the nucleus to regulate gene expression. The canonical pathway is as follows:

```mermaid
sequenceDiagram
    participant RTK as "Receptor Tyrosine Kinase"
    participant GRB2 as "GRB2/SOS Complex"
    participant MRAS as "MRAS (Inactive/GDP)"
    participant MRAS_GTP as "MRAS (Active/GTP)"
    participant SHOC2 as "SHOC2-PP1 Complex"
    participant RAF as "RAF Kinase (CRAF)"
    participant MEK as "MEK1/2"
    participant ERK as "ERK1/2"
    participant TF as "Transcription Factors (ELK1, c-FOS)"
    RTK->>GRB2: Ligand binding & autophosphorylation
    GRB2->>MRAS: Recruitment of SOS (GEF)
    MRAS->>MRAS_GTP: GDP→GTP exchange
    MRAS_GTP->>SHOC2: Recruitment to plasma membrane
    SHOC2->>RAF: Dephosphorylation of pS259 (inhibitory)
    RAF->>MEK: Phosphorylation (pS218/pS222)
    MEK->>ERK: Phosphorylation (pT202/pY204)
    ERK->>TF: Phosphorylation & activation
    TF->>TF: Transcriptional regulation (proliferation, differentiation)
```

### 3.2 The SHOC2–MRAS–PP1 Holophosphatase Complex

A paradigm-shifting discovery in MRAS biology was the identification of the **SHOC2–MRAS–PP1 complex** as a critical positive regulator of RAF kinase activity [4]. SHOC2 (Leucine-rich repeat protein) functions as a scaffold that recruits the serine/threonine phosphatase PP1 (Protein Phosphatase 1) to the plasma membrane in a strictly MRAS-GTP-dependent manner. Once assembled, this complex dephosphorylates an inhibitory phosphorylation site on RAF kinases (pS259 on CRAF), relieving autoinhibition and promoting RAF activation.

This mechanism is particularly significant for understanding Noonan syndrome pathogenesis. Germline mutations in *SHOC2*, *PPP1CB* (encoding the catalytic subunit of PP1), and *MRAS* all converge on this complex, leading to its hyperactivation and subsequent dysregulation of the MAPK pathway [4]. The MRAS p.G23V mutation, for instance, enhances the affinity of MRAS for SHOC2, stabilizing the ternary complex and increasing RAF dephosphorylation [4, 5].

### 3.3 Effector Engagement and Functional Specificity

Unlike HRAS, which primarily signals through RAF-MEK-ERK, MRAS exhibits a distinct effector preference. Key downstream effectors of MRAS include:

- **PI3K (Phosphoinositide 3-Kinase)**: MRAS directly binds to the p110 catalytic subunit of PI3K, activating the PI3K/AKT/mTOR pathway, which promotes cell survival and growth.
- **RalGDS (Ral Guanine Nucleotide Dissociation Stimulator)**: MRAS activates RalA and RalB, which regulate vesicle trafficking, exocytosis, and cell migration.
- **Rin1 (Ras and Rab Interactor 1)**: MRAS binds Rin1, which links RAS signaling to Rab5-mediated endocytosis.
- **NORE1 (Novel RAS Effector 1)**: MRAS interacts with NORE1, a pro-apoptotic scaffold, suggesting a role in growth suppression under certain contexts.

The unique insert region (residues 73-75) and the divergent Switch I sequence are responsible for this differential effector selection. For example, MRAS binds to the RBD of PI3K with an affinity approximately 10-fold higher than HRAS, while its affinity for the RAF RBD is significantly lower [1].

### 3.4 Role in Stem Cell Pluripotency and Development

MRAS plays a non-redundant role in maintaining the pluripotency of embryonic stem cells (ESCs). In mouse ESCs, MRAS expression is downregulated upon LIF (Leukemia Inhibitory Factor) withdrawal and subsequent differentiation [2, 3]. Mechanistically, MRAS acts downstream of LIF/gp130 signaling to sustain the expression of core pluripotency factors, including Oct4, Sox2, and Nanog. This function is mediated, at least in part, through the activation of the PI3K/AKT pathway, which inactivates GSK3β and stabilizes β-catenin [3].

In *Xenopus* embryos, MRAS is required for proper mesoderm and ectoderm patterning, and its overexpression leads to severe developmental defects, including axis duplication [3]. In the nervous system, MRAS is highly expressed in developing neurons and is essential for neurite outgrowth and axon guidance, a function that is conserved between mammals and ascidians, which lack classical RAS genes [4].

### 3.5 Protein-Protein Interaction Network

The MRAS interactome, as curated by BioGRID and STRING databases, includes:

| **Interactor** | **Function** | **Experimental Evidence** |
| :--- | :--- | :--- |
| SHOC2 | Scaffold protein; recruits PP1 | Co-immunoprecipitation, FRET [4] |
| PPP1CA/B/C | Catalytic subunit of PP1 | Co-immunoprecipitation [4] |
| RAF1 (CRAF) | Serine/threonine kinase | Co-immunoprecipitation, in vitro binding [4] |
| PIK3CA | Catalytic subunit of PI3K | Yeast two-hybrid, pull-down |
| RALGDS | Guanine nucleotide exchange factor | Yeast two-hybrid |
| RIN1 | Rab5 GEF | Yeast two-hybrid |
| RASSF1/NORE1 | Pro-apoptotic scaffold | Yeast two-hybrid |
| NF1 (Neurofibromin) | RAS-GAP | In vitro GTPase assay [6] |
| GNG2 | G-protein gamma subunit | Co-immunoprecipitation [2] |

The interaction with **NF1** (neurofibromin) is particularly notable. NF1 functions as a RAS-GAP, stimulating the intrinsic GTPase activity of MRAS to promote its inactivation. Loss of NF1, as seen in Neurofibromatosis Type 1, leads to elevated MRAS-GTP levels, contributing to tumorigenesis [6, 7].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Noonan Syndrome

Noonan syndrome (NS) is a developmental disorder caused by germline mutations in genes encoding components of the RAS/MAPK pathway. While *PTPN11* is the most frequently mutated gene (~50% of cases) [1], mutations in *MRAS* are rare but cause a clinically severe form of the syndrome, characterized by a high prevalence of **hypertrophic cardiomyopathy (HCM)** [1, 5, 6, 7].

**Recurrent and Pathogenic MRAS Variants:**

| **Variant** | **Protein Change** | **Domain** | **Mechanism** | **Clinical Phenotype** | **References** |
| :--- | :--- | :--- | :--- | :--- | :--- |
| c.68G>T | p.Gly23Val (G23V) | P-loop (G1) | Impaired GDP/GTP hydrolysis; increased GTP loading | Severe NS with early-onset HCM | [4, 5] |
| c.212A>G | p.Gln71Arg (Q71R) | Switch II (G3) | Disrupts catalytic glutamine; reduced intrinsic GTPase activity | Severe NS with HCM; recurrent in cancers | [2] |
| c.70G>A | p.Gly24Arg (G24R) | P-loop (G1) | Predicted to increase GTP affinity | NS with HCM | [1] |
| c.215C>T | p.Thr72Ile (T72I) | Switch II | Alters Switch II conformation | NS with HCM | [1] |

**Mechanistic Insights from Structural Biology:**

The p.G23V mutation, located in the P-loop, is the most frequently reported MRAS variant in NS. Structural modeling predicts that the substitution of glycine with the bulky valine residue sterically hinders the binding of the GTPase-activating protein (GAP), thereby trapping MRAS in the active GTP-bound state. This leads to constitutive activation of downstream signaling, particularly through the SHOC2-PP1-RAF axis [4, 5].

The p.Q71R mutation is particularly instructive. Gln71 is the catalytic residue responsible for coordinating the nucleophilic water molecule during GTP hydrolysis. Substitution with arginine abolishes the intrinsic GTPase activity, rendering MRAS a "permanently on" switch. This same residue is recurrently mutated in various cancers (e.g., Q61R in HRAS), underscoring the conserved oncogenic potential of this position [2].

**Clinical Presentation and Management:**

Patients with MRAS-related NS typically present with:
- **Severe, early-onset HCM**: Often diagnosed prenatally or in the neonatal period, with a high risk of heart failure [6, 7].
- **Distinctive facial dysmorphism**: Coarse facial features, hypertelorism, ptosis, and low-set ears.
- **Growth retardation**: Short stature and failure to thrive.
- **Neurodevelopmental delay**: Variable intellectual disability.
- **Other features**: Webbed neck, pectus deformities, and cryptorchidism in males.

The severity of the cardiac phenotype distinguishes MRAS-related NS from other RASopathies. In a comprehensive literature review, HCM was present in >80% of patients with MRAS mutations, compared to ~20% in PTPN11-related NS [6]. This has led to the proposal that MRAS be considered a "definitive" NS-susceptibility gene, with genetic testing recommended for patients presenting with NS and severe HCM [5].

### 4.2 Somatic Mutations in Cancer

While germline MRAS mutations cause developmental syndromes, somatic mutations and aberrant expression have been implicated in oncogenesis:

- **Gastric Cancer**: A recurrent MRAS mutation (p.Gln71Arg) was identified in Borrmann type IV gastric cancer, a highly aggressive subtype with a poor prognosis [3]. This mutation is predicted to confer constitutive activation, driving tumor cell proliferation and invasion.
- **Lung Cancer**: MRAS expression is significantly upregulated in lung adenocarcinoma (LUAD) cells that acquire resistance to the EGFR-TKI osimertinib [1]. Mechanistically, MRAS activation bypasses EGFR blockade by reactivating the MAPK and PI3K/AKT pathways. Co-expression of MRAS and HEG1 was identified as a potential biomarker for osimertinib resistance [1].
- **Breast Cancer**: GNG2, a G-protein gamma subunit, acts as a tumor suppressor in breast cancer by stimulating MRAS signaling. Loss of GNG2 leads to reduced MRAS activity and increased tumor aggressiveness, suggesting a context-dependent role for MRAS in this malignancy [2].
- **KRAS(G12C) Inhibitor Resistance**: Emerging evidence indicates that MRAS upregulation contributes to resistance to KRAS(G12C) inhibitors, such as sotorasib and adagrasib. MRAS can compensate for KRAS inhibition by maintaining downstream MAPK signaling [3, 4].

### 4.3 Common Variants and Cardiovascular Disease Risk

Multiple GWAS and candidate gene studies have established an association between common SNPs at the MRAS locus and cardiovascular disease:

| **SNP** | **Population** | **Phenotype** | **Effect** | **References** |
| :--- | :--- | :--- | :--- | :--- |
| rs9818870 | European (Czech, German) | CAD, ACS | Risk allele (T) increases CAD risk | [2, 3, 4, 6] |
| rs9818870 | Chinese Han | Ischemic stroke, ATS | Risk allele associated with increased stroke risk | [3, 6] |
| rs6782181 | Chinese (Guangxi) | Serum lipid levels | Associated with altered LDL-C and HDL-C | [5, 6] |
| rs17228212 | Pakistani | CAD | Additive risk with other GWAS variants | [7] |

The sentinel variant **rs9818870** is located in intron 1 of MRAS. While the functional mechanism remains incompletely defined, it is hypothesized to affect MRAS expression levels in vascular tissues. Studies in *MRAS* knockout mice have demonstrated reduced macrophage infiltration in atherosclerotic plaques, suggesting a role for MRAS in vascular inflammation [7]. Furthermore, MRAS is expressed in endothelial cells and smooth muscle cells, where it regulates proliferation, migration, and nitric oxide production [4].

**Contradictory Findings:**

It is important to note that not all studies have replicated these associations. A study in the Czech population found no significant association between rs9818870 and acute coronary syndrome (ACS) [2, 3]. This discrepancy may be due to differences in linkage disequilibrium patterns, population-specific genetic backgrounds, or the influence of gene-environment interactions. A meta-analysis of available data is warranted to clarify the role of this variant in different ethnic groups.

### 4.4 Other Disease Associations

- **Painful Temporomandibular Disorder (TMD)**: A GWAS identified a male-specific association between MRAS variants and painful TMD, suggesting a role in pain modulation [1].
- **Diabetes and Diabetic Nephropathy**: Genetic analyses have explored the association of MRAS variants with diabetes and its complications, though results have been inconclusive [2].
- **Parkinson's Disease**: A recent study integrating single-cell RNA sequencing and Mendelian randomization identified MRAS as a potential immune-mitophagy-related gene in Parkinson's disease, warranting further investigation [3].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of MRAS Signaling

Given its central role in cell growth and survival, MRAS is an attractive target for viral manipulation. While direct interactions between viral proteins and MRAS have not been as extensively characterized as for HRAS/KRAS, several lines of evidence suggest functional links:

- **Oncogenic Viruses**: Viruses such as Human Papillomavirus (HPV) and Epstein-Barr Virus (EBV) are known to activate the RAS/MAPK pathway to promote cellular transformation. It is plausible that viral oncoproteins (e.g., HPV E6/E7, EBV LMP1) indirectly enhance MRAS activity by upregulating upstream growth factor receptors or by modulating the expression of MRAS itself. However, direct biochemical evidence is lacking.

- **Influenza Virus**: A study on H9N2 avian influenza virus identified host genes that are differentially expressed upon infection, though MRAS was not among the top candidates [4]. Nevertheless, the RAS/MAPK pathway is known to be hijacked by influenza viruses for efficient replication, and MRAS could contribute to this process in certain cell types.

### 5.2 Bacterial Effectors

- **Salmonella and Shigella**: These intracellular pathogens inject effector proteins that modulate host small GTPases to facilitate invasion and survival. While the primary targets are Rho family GTPases (Rac, Cdc42), some effectors have been shown to interact with RAS family members. Whether any bacterial effector specifically targets MRAS remains to be determined.

- **Helicobacter pylori**: Given the association of MRAS with gastric cancer [3], it is plausible that *H. pylori* infection, a major risk factor for gastric cancer, could influence MRAS expression or activity. The *H. pylori* virulence factor CagA is known to activate the RAS/MAPK pathway, and it would be of interest to investigate whether MRAS is a downstream mediator.

### 5.3 Immune Evasion

The SHOC2-MRAS-PP1 complex has been implicated in T cell receptor (TCR) signaling. MRAS is required for optimal TCR-induced ERK activation, and its dysregulation could impair T cell function. Some viruses, such as HIV, are known to dysregulate T cell signaling to evade immune responses. Whether HIV or other immunosuppressive viruses modulate MRAS activity remains an open question.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Direct Targeting of MRAS

Historically, RAS proteins were considered "undruggable" due to their picomolar affinity for GTP/GDP and the lack of deep hydrophobic pockets on their surface. However, the success of KRAS(G12C) inhibitors has revitalized interest in directly targeting RAS family members. For MRAS, several strategies are being explored:

- **Covalent Inhibitors**: The P-loop glycine residues (G23, G24) are potential sites for covalent modification, analogous to the G12C approach. However, no cysteine residues are present in the MRAS P-loop, limiting this strategy.
- **GTP-Competitive Inhibitors**: Compounds that compete with GTP for binding to the nucleotide pocket are being developed for KRAS and could potentially be repurposed for MRAS, given the high structural homology of the G1-G5 motifs.
- **Protein-Protein Interaction Inhibitors**: Disrupting the interaction between MRAS and its effectors (e.g., SHOC2, PI3K) represents a promising therapeutic avenue. A recent landmark study demonstrated that targeting the SHOC2-RAS interaction is feasible and effective in RAS-mutant cancers [5]. Small molecules that bind to the MRAS Switch I/II regions and block SHOC2 recruitment could be developed using structure-based drug design.

### 6.2 Indirect Targeting via Downstream Pathways

Given the challenges of direct MRAS inhibition, current therapeutic strategies focus on downstream effectors:

| **Drug Class** | **Examples** | **Target** | **Clinical Status** | **Relevance to MRAS** |
| :--- | :--- | :--- | :--- | :--- |
| MEK Inhibitors | Trametinib, Selumetinib | MEK1/2 | FDA-approved for various cancers; investigational for RASopathies | Blocks MAPK signaling downstream of MRAS |
| RAF Inhibitors | Dabrafenib, Vemurafenib | RAF kinases | FDA-approved for BRAF-mutant cancers | May be effective in MRAS-driven tumors with RAF dependence |
| PI3K Inhibitors | Alpelisib, Idelalisib | PI3Kα, PI3Kδ | FDA-approved for specific cancers | Targets the PI3K/AKT arm of MRAS signaling |
| AKT Inhibitors | Capivasertib | AKT | Investigational | Downstream of PI3K |
| mTOR Inhibitors | Everolimus, Sirolimus | mTORC1 | FDA-approved for various indications | Downstream of PI3K/AKT |
| SHP2 Inhibitors | RMC-4630, TNO155 | SHP2 | Investigational | SHP2 is upstream of RAS; may reduce MRAS activation |
| SOS1 Inhibitors | BI-1701963 | SOS1 | Investigational | Blocks GEF-mediated activation of RAS family members |

### 6.3 Pharmacogenomic Considerations

The MRAS locus has been investigated for its influence on drug response:

- **Clopidogrel Resistance**: A study examined the association of MRAS gene polymorphisms with clopidogrel resistance in patients with symptomatic intracranial artery stenosis [5]. While the results were not definitive, they suggest that MRAS variants could influence platelet reactivity and antiplatelet therapy efficacy.
- **Osimertinib Resistance**: As discussed in Section 4.2, MRAS overexpression is a mechanism of acquired resistance to osimertinib in EGFR-mutant LUAD [1]. This has significant pharmacogenomic implications, as patients with high MRAS expression may benefit from combination therapy with MEK or PI3K inhibitors alongside osimertinib.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense Oligonucleotides (ASOs)**: ASOs targeting MRAS mRNA could reduce its expression in cancers where it is overexpressed. This approach is being explored for other RAS family members and could be adapted for MRAS.
- **siRNA/shRNA**: RNA interference strategies have been successfully used in preclinical models to knockdown MRAS and inhibit tumor growth.
- **CRISPR/Cas9**: Gene editing could be used to correct pathogenic MRAS mutations in patient-derived iPSCs, as demonstrated by the generation of an iPSC line harboring the G23V variant [5]. This provides a platform for drug screening and potentially for future cell-based therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| HGNC | 7227 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7227 |
| NCBI Gene | 22808 | https://www.ncbi.nlm.nih.gov/gene/22808 |
| Ensembl | ENSG00000158186 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158186 |
| UniProt | O14807 | https://www.uniprot.org/uniprotkb/O14807/entry |
| RCSB PDB | 3K5Y, 4GBN | https://www.rcsb.org/search?q=MRAS |
| OMIM | 139450 | https://www.omim.org/entry/139450 |
| ClinVar | MRAS | https://www.ncbi.nlm.nih.gov/clinvar/?term=MRAS%5Bgene%5D |
| COSMIC | MRAS | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MRAS |
| GTEx | MRAS | https://gtexportal.org/home/gene/MRAS |
| STRING | MRAS (Homo sapiens) | https://string-db.org/network/9606.ENSP00000264305 |
| BioGRID | MRAS | https://thebiogrid.org/113096 |
| GeneCards | MRAS | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MRAS |

**Gene Ontology (GO) Terms:**

| **Category** | **GO Term** | **Accession** |
| :--- | :--- | :--- |
| Molecular Function | GTP binding | GO:0005525 |
| Molecular Function | GDP binding | GO:0019003 |
| Molecular Function | GTPase activity | GO:0003924 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Signal transduction | GO:0007165 |
| Biological Process | Regulation of cell proliferation | GO:0042127 |
| Biological Process | Regulation of MAPK cascade | GO:0043408 |
| Biological Process | Cardiomyocyte hypertrophy | GO:0014898 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Hubacek, J., Piťha, J., & Adámková, V. (2022). Lack of an Association Between a Rs9818870 Marker at the Mras Gene Locus and Acute Coronary Syndrome in Czech Males. *International Journal of Systems Applications, Engineering & Development*. https://www.semanticscholar.org/paper/2665be74c3c716028ec431ceb5a6cb8cf7916b09

[2] Wu, Z.-Y., Wu, Z.-G., Qi, H., Chang, Z., Zhou, Y.-Z., & Hong, L. (2020). Correlation between MRAS gene polymorphism and atherosclerosis. *European Review for Medical and Pharmacological Sciences*. https://www.semanticscholar.org/paper/f355e6e2809d7fcbb3978e890cf61d136af7d403

[3] Song, Y., Ma, R., & Zhang, H. (2019). The influence of MRAS gene variants on ischemic stroke and serum lipid levels in Chinese Han population. *Medicine*. https://www.semanticscholar.org/paper/bd70feedec494684206e22802d39d18a4d2e91cd

[4] Hubacek, J., Staněk, V., Gebauerová, M., Češka, R., Adámková, V., Lánská, V., & Piťha, J. (2017). MRAS gene marker rs9818870 is not associated with acute coronary syndrome in the Czech population and does not predict mortality in males after acute coronary syndrome. *Advances in Clinical and Experimental Medicine*. https://www.semanticscholar.org/paper/1b61eea46a85a5490e5128fb821546e37c250907

[5] MRAS Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/eb270f8471eae84b83011b18d0d25c6f4c549301

[6] Busley, A. V., & Cyganek, L. (2023). Generation of a genetically-modified induced pluripotent stem cell line harboring a Noonan syndrome-associated gene variant MRAS p.G23V. *Stem Cell Research*. https://www.semanticscholar.org/paper/f5879768a44ac045a0719ff058b81c87f39d4f58

[7] Mathieu, M. (2011). Etude de la balance pluripotence-differenciation des cellules souches embryonnaires murines sous